RGCC International
RGCC offers blood tests that isolate circulating tumour cells and profile them to guide treatment choices and to track disease over time, sold worldwide to patients as well as physicians.
Overview
RGCC International markets liquid biopsy tests based on circulating tumour cells: molecular profiling of the cells to suggest which drugs and natural substances might act on them, and serial counts to monitor disease activity and treatment response. Future of Cancer Care Today lists it as worldwide and patient- or physician-ordered. The tests sit outside mainstream guideline practice, and readers should weigh the evidence for chemosensitivity testing on circulating cells accordingly.
Similar pages
not linked directly; found by shared links- CompanyCNSide Diagnostics
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA) and the tag fcct-directory.
- CompanyCanCertain
Shares Circulating tumour cell capture and the tag fcct-directory.
- CompanyBelay Diagnostics
Shares Liquid biopsy (ctDNA) and the tag fcct-directory.